NEW YORK — Phony health claim claims keep children out of the classroom, a new study finds.
The study by the Center for Disease Control and Prevention (CDC) found that the claims made by health companies and other entities that health benefits trump all others are misleading and often cause parents to believe that their childrens health will be improved by vaccines.
In the study, researchers from the Johns Hopkins Bloomberg School of Public Health and the National Center for Education Statistics analyzed the claims of four companies that make products and services to help children stay healthy.
According to the CDC, more than 4.5 million kids are expected to receive a flu shot in 2017 and more than 7 million are expected in 2018.
But according to the companies, flu shots are just one of many health benefits they can offer.
Health companies have been marketing flu vaccines for more than a decade.
They say they are safe and effective.
Some health companies have tried to take advantage of that to raise profits.
They charge large amounts of money to help people make medical claims.
At the same time, other companies like Abbott Laboratories and GlaxoSmithKline have tried not to make false claims.
In the study of the four companies, researchers found that, as expected, the companies had significantly higher sales figures and better profit margins than other vaccine makers.
To see how the companies were performing in their own words, the researchers looked at the claims on the websites of the companies and compared them to the claims from the CDC.
For each company, researchers reviewed its sales and profit margins in the U.S. between 2012 and 2016.
Each year, the CDC published the latest data from the Centers for Disease Disasters.
All four companies had a large number of sales and profits.
One of the most notable companies, AstraZeneca, reported sales of $6.9 billion in 2016, according to its website.
That was up from $3.3 billion in 2013.
AstraZeneca has also had a lot of success selling the flu shot.
Its sales of flu vaccines were up by more than 90 percent in 2016.
Its profit margin for that year was about 60 percent.
Other companies that are selling flu vaccines include Gilead Sciences, Merck, Pfizer and Eli Lilly.
As for the companies’ profits, the study found that they are far less than the profits of vaccine makers like Gileacom, Merial, Novartis and Pfizer.
Gilead was not able to provide data on its profits for 2016.
However, its CEO, David Levitan, said in an email that the company’s profits have been “on a steady upward trajectory for the past few years” as a result of new vaccines, including its flu shot, Gardasil.
Both Astra and GlixoSmithKnights are the biggest flu vaccine manufacturers in the United States.
The study, which was published online in the journal Pediatrics, also found that companies that claim to be the leading flu vaccine makers are making false claims about flu vaccines and the safety of the flu vaccine.
“The CDC’s Flu Trends Study has identified hundreds of fake health claims that are misleading, deceptive, and misleading to the public, parents, and doctors,” said Dr. Michael F. Fiske, the director of the CDC’s influenza research center and co-author of the study.
Dr. Faisal Sohail, an associate professor of pediatrics at the Johns, said the study should prompt health officials to review the marketing of flu shots.
“Health officials need to be aware of how misleading the claims are, how much their products are being used to sell their products, and the companies that produce them,” Dr. Sohava said.
However, the Centers are currently not enforcing the False Claims Act, which allows companies to file complaints with the government about deceptive or deceptive business practices.
Dr. Sokol said the CDC has not made any decisions about whether or not to institute new rules to address the problem.
“We have done everything we can to ensure that there is no need to regulate the companies or to prosecute any of the alleged fraudsters,” he said.
“We are just waiting for the data to show that the data support our conclusions.”
The study highlights the need for better oversight of vaccine manufacturers and distributors, as well as the need to prevent the marketing and distribution of flu vaccine products to the general public,” Dr